Navigation Links
Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays
Date:3/27/2009

Rapid, actionable intelligence in 2 hours

CHICAGO, March 27 /PRNewswire/ -- Celsis International plc (LSE: CEL.L), a global leader in rapid microbial detection solutions for industry, today announces the launch of Celsis ReACT(TM), the first easy-to-use RNA-based assay for detecting objectionable organisms quickly and definitively without the need for expensive equipment or specialized training.

Manufacturers of pharmaceutical, beauty and home care products using Celsis Rapid Detection systems for their primary screening of raw materials, in-process and finished goods can now utilize this new RNA-based assay to obtain a fast, 2-hour result on samples that test positive for microbial contamination. Celsis ReACT assays use proprietary selections of ribosomal RNA sequences to confirm or to rule out the presence of Gram-negative organisms, Staph. aureus, yeast and mold, and can be customized for facility-specific or wild strain organisms.

"Serious contamination events, while somewhat rare, do happen. When they occur they can cost companies hundreds of thousands, if not millions of dollars," explained Jay LeCoque, Celsis CEO. "We developed Celsis ReACT for our customers who have asked for a way to quickly and easily determine if they have an objectionable organism, so they can minimize the financial impact to their operations and bottom line."

The faster a company can confirm that a sample has been contaminated by an objectionable organism, the faster the contaminated batch can be stopped before it reaches the production line or, even worse, is released for sale. In addition, a faster reaction means fewer potentially contaminated additional batches will be produced, thus significantly reducing the financial impact of lost product and product disposal.

Celsis customers will be able to use Celsis ReACT following the primary Celsis AKuScreen(TM) assay, which definitivel
'/>"/>

SOURCE Celsis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes
2. Celsis Launches RapiScreen(TM) Beverage Microbial Screening System
3. Celsis Receives Frost & Sullivan 2008 Best Practices Award
4. PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace
5. DNA2.0 Introduces Freedom of Expression With a New Family of Bacterial Expression Vect:ors
6. Lumenis(R) Introduces Cost-Saving Innovations at the 2009 American Academy of Dermatology (AAD) Annual Meeting
7. GeneCopoeia Introduces Genome-Wide MicroRNA (miRNA) Functional Analysis Tools
8. Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France
9. Sigma-Aldrich Introduces MISSION(R) LentiPlex(TM) Pooled shRNA Libraries to Enable Rapid Whole Genome Screening in Primary Cells, Stem Cells or Tumor Cells
10. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
11. Max Muscle Introduces First-Ever Probiotics Protein Bar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...e-FirstCall/ -- BlueFire Ethanol Fuels, Inc. (OTC ...ng the world,s transportation fuel paradigm throug...ic wastes, has been ranked number 19 on the Biofu...ioenergy;" the company,s second consecutive year i...Ethanol among the top 20 bioenergy companies for t...
(Date:12/3/2009).../ -- Nikon Corporation, an innovator of advanced o...gned a licensing agreement with Harvard University...ptical Reconstruction Microscopy (STORM) technolog...nufacture STORM enabled microscopy systems and mar...ration President, Mr. Michio Kariya, and Nikon Ins...
(Date:12/3/2009)...FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: ...elopment of compounds for the treatment of cardiov...t it has completed the last patient visit in its P...The FDG-PET trial enrolled 52 patients and was car...ing Massachusetts General Hospital, Mount Sinai Sc...
(Date:12/3/2009)...ire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. ...ase its financial results for the second quarter o...m. EST and will host a conference call and webcast...ame day. ,, Peregrine,s senior management will ...nded October 31, 2009 and will review recent opera...
Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2
...y unveils landmark program to help clients avoid c...n collecting outcomes data, LINCOLN, R.I., July 1... questioning the integrity of outcomes data in cli...rsy has been in the news. The,truth is, no matter ...d,for, mistakes are easy to make and difficult to ...
...TON, N.J., July 15 Pharmasset, Inc.,(Nasdaq: VRU...itive,agreements dated July 14, 2008 with a select...0 shares of its common stock in a "registered,dire...e the shares at a,purchase price of $17.85 per sha...5.9 million to Pharmasset, before deducting placem...
...A, July 15 CryoLife, Inc. (NYSE: CRY ),a biomate...y, announced,today that second quarter 2008 financ... 2008. The Company will hold a teleconference call... 31, 2008, to discuss the,results, followed by a q...erson, president and CEO of CryoLife, Inc., To li...
Other Biology Technology:QualityMetric Announces QM Certified Scoring Program 2Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock 2Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock 3CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results 2
(Date:12/4/2009)...matical model of heart cells, University of Iowa i...al enzyme, calmodulin kinase II (CaM kinase), disr... The study, which also involved Columbia Universit...S Computational Biology . , "Recently, research...nase II as a critical regulator of the heart,s res...
(Date:12/3/2009)... N.J., Dec. 3 BIO-key In...ader in wireless public safety and finger-based bi... majority of its shareholders at a Special Shareho...ompany,s Law Enforcement Division to Interact911 M... cast in favor and 1.2% were opposed. ,, (Logo:...
(Date:12/3/2009)...learn new information and adapt to changes in our ...emories, appears to lie in the minute junctions wh...udy by NYU Langone Medicine Center researchers. Th...al Nature . , The scientists, led by Wen-Biao ...uroscience at NYU School of Medicine, discovered t...
Breaking Biology News(10 mins):U-Iowa study helps advance heart-related research 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Lifelong memories linked to stable nerve connections 2AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 1AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 2AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 3AMB Property Corporation 28R 29 Leases 440 000 SF in Hamburg 51000 4NIA Says Health Care Will Cause U S Dollar Collapse 50998 1NIA Says Health Care Will Cause U S Dollar Collapse 50998 2NIA Says Health Care Will Cause U S Dollar Collapse 50998 3Spa Chefs Prepare You for a Healthy Summer 50996 1Spa Chefs Prepare You for a Healthy Summer 50996 2
...niversity Medical Center scientists have developed...ents with early-stage lung cancer will need chemot...xic regimen of drugs. , The test has the potenti...nding chemotherapy for patients who are currently ...Duke,s Institute for Genome Sciences & Policy....
...wing gentle puffs of air onto a mouse,s whiskers a...iscovering that a long-overlooked signaling system... , The work is the latest in a growing body of evi...ytes aren,t simply support cells but are stars of ...he University of Rochester Medical Center who did ...
...ein long thought to provide only mechanical suppor...ling apart turns out to have much wider utility. I...d to also influence wound healing and maintain the... to Johns Hopkins researchers. , The wound-healing...eds light on how the body repairs wounds and may h...
Other Biology News:First-ever genomic test predicts which lung cancer patients need chemotherapy to live 2First-ever genomic test predicts which lung cancer patients need chemotherapy to live 3First-ever genomic test predicts which lung cancer patients need chemotherapy to live 4Flick of whiskers helps tease out brain's 'shadow' signaling system 2Flick of whiskers helps tease out brain's 'shadow' signaling system 3Bedsores and bald hides: Novel roles revealed for a 'scaffolding' protein 2Bedsores and bald hides: Novel roles revealed for a 'scaffolding' protein 3
Nick Translation System from Invitrogen
...ble, easy-to-use and makes identifying your sample...asy to use Labels withstand extreme lab conditio...te stamp Laboratory symbols Affordable-every t...re efficient Banner mode for general labeling ...
cAMP[125I] Direct SPA Screening Biotrak Assay from GE Healthcare, formerly Amersham Biosciences
E. coli Expression System with Gateway Technology from Invitrogen
Biology Products: